Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Food and Drug Administration recently approved a generic formulation of Gilead Sciences’ antiretroviral Truvada.
Although more research on antiretroviral linked bone loss is needed, the overall health benefits of early treatment outweigh such a risk.
New trial compares Descovy to Truvada.
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
Gilead Sciences has filed for approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV with the European Medicines Agency.
Two documented cases of men taking Viread (tenofovir), one of two drugs in Truvada (tenofovir/emtricitabine), for hep B and contracting HIV.
Truvada as pre-exposure prophylaxis (PrEP), unapproved in the United Kingdom, could dramatically reduce new infections among gay men there.
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
Truvada as pre-exposure prophylaxis (PrEP) against HIV has comparable safety to aspirin, at least for the short- and medium-term.
Following years of apparent stagnation in the U.S. fight against HIV, reports now suggest that things are looking up. What’s the full story?
Those who develop resistance to Truvada after contracting HIV shortly before or while taking PrEP do not maintain such resistance for long.
The rate dropped by nearly 20 percent during the past decade, but such good news is tempered by uneven progress among different risk groups.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.